Медицинская биохимия
736 статей · 10 журналов
Журналы подкатегории (10)
- Biomarker Research · Springer Nature (344)
- Clinica Chimica Acta · Elsevier (105)
- Transfusion Clinique et Biologique · Elsevier (60)
- Advances in Biomarker Sciences and Technology · Elsevier (56)
- Revue Francophone des Laboratoires · Elsevier (56)
- Translational Research · Elsevier (43)
- Clinics in Laboratory Medicine · Elsevier (41)
- Non-coding RNA Research · Elsevier (18)
- MedComm · Wiley (13)
- Forensic Toxicology · Springer Nature (0)
-
Multi-omics, multi-tissue analysis reveal role of extracellular matrix remodeling and sphingolipid homeostasis in edematous malnutrition (kwashiorkor)
Abstract Background Edematous malnutrition, aka kwashiorkor, is a phenotype of severe malnutrition whose pathophysiology remains poorly understood. Methods In this case-control study, we employed plasma lipidomics, metabolomics, and...
-
Synergistic efficacy of the EGFR inhibitor osimertinib with the XPO1 inhibitor selinexor in T-cell acute lymphoblastic leukemia
Abstract Background T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy with poor prognosis, especially in relapsed/refractory patients. Aberrant PI3K/AKT/mTOR and NOTCH1 signaling converge on c-MYC to drive...
- Immune checkpoints: cross-disease insights and clinical dilemmas
-
CD73-targeted CAR-NK cell therapy displays potent antitumor activity and translational potential in relapsed/refractory lung adenocarcinoma
Abstract Background Relapsed/refractory (R/R) lung adenocarcinoma (LUAD) remains a clinical challenge with limited therapies and poor prognosis. CAR‑NK cell therapy has shown promise in solid tumors, but its efficacy is limited by both...
- IL-6/CD147-augmented CAR macrophages enhance the antitumor activity of CAR-T cells in solid tumor models
-
Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial
Abstract Background The revision of the WHO classification of CNS tumours now distinguishes grade 4 diffuse gliomas by their molecular features, but tailored treatment is yet to be standardised. Glioblastoma (isocitrate dehydrogenase (...
- Impact of SARS-CoV-2 vaccination on cancer trends: a nationwide interrupted time series study
- Ex vivo JAK and TNF inhibitor–modulated immune signatures guide first-line therapy selection in rheumatoid arthritis
- Ubiquitin signaling in tumor-associated macrophage reprogramming: mechanisms and therapeutic opportunities in cancers
- Persistent CAR-T donor cells contribute to mixed chimerism with cytopenia after CAR-T-bridged allo-HSCT: rescue by CAR-target-knockout DLI in three cases
- Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy
- Peripheral blood CXCL1 serves as a non-invasive dynamic biomarker for intratumoral colonization of attenuated Salmonella
- Dynamic regulation of H3K9 modifications in cancer: pathogenesis and targeted therapies
- ZDHHC5-mediated S-palmitoylation of NOD2 drives neutrophil extracellular trap formation via mitophagy to exacerbate inflammation in COPD
- Low-dose radiotherapy as an immunomodulator in cancer: dose-specific mechanisms and hybrid high-dose/low-dose strategies
- RNA N4-acetylcytidine modification in health and cancer: molecular mechanisms, cellular plasticity, and therapeutic opportunities
-
The immune phenotype of circulating tumor cells: from escape mechanisms to immunotherapy navigation
Abstract Circulating tumor cells (CTCs) must survive immune attack in the bloodstream before they can contribute to distant metastasis. Their immune phenotype, including checkpoint ligands, antigen-presentation molecules, and...
-
The NFIL3-MYC signaling axis: a novel therapeutic target and prognostic marker in high-risk multiple myeloma
Abstract Background Drug resistance causes tumor relapse, limits the outcomes of patients with high-risk multiple myeloma (MM), and requires the development of targeted therapeutics. Increased Notch signaling promotes drug resistance in...
- Beyond a cancer stem cell marker: molecular state dependent functions of CD133 and state targeted therapy
- Pannexin 1 expression in circulating progenitor marker-positive cells is associated with senescence and cardiovascular risk
- First-in-human phase Ia study of the covalent TEAD palmitoylation inhibitor BPI-460372 in patients with advanced solid tumors: pharmacokinetics, exposure-limited dosing, and early antitumor activity
- Monocyte Galectin-9 is associated with CD8⁺ T-cell dysfunction and early relapse after haploidentical hematopoietic stem cell transplantation
-
ZNF292 mutations impair RNA and protein biosynthesis defining an adverse prognostic subset in early-stage chronic lymphocytic leukemia
Abstract Background ZNF292 alterations are recurrently detected in patients with chronic lymphocytic leukemia (CLL), occurring in 3%-6% of patients as mutations and in 2% as 6q deletions. Although preliminary evidence suggested an...
- Advances in molecular pathobiology of PCNSL – towards clinical implementation of novel diagnostics and therapeutics
- Cell death in ischemia-reperfusion injury: beyond a single-cell-death perspective
- Megakaryocytes in myelofibrosis: mechanisms of fibrotic niche remodeling and therapeutic implications
-
Genetic orchestration of the primary central nervous system lymphoma microenvironment
Abstract Primary central nervous system lymphoma (PCNSL) of the CNS is a distinct entity of diffuse large B-cell lymphoma (DLBCL). CNS lymphomas primarily occur in immune-privileged sites and tend to be confined to extranodal locations...
- A biomarker-driven approach to targeting polyamine depletion in triple negative breast cancer
- Neural–tumor interactions: bidirectional regulatory mechanisms and nervous system-targeted tumor therapeutic strategies
- Metabolic-inflammatory index CTI identifies high-risk early-stage natural killer/T-cell lymphoma and informs a novel prognostic model